Drugsters Back on Top in Latest Health Care Reform Deal

What the press refers to as “tweaks” in the new version of health care legislation would appear to hand Big Pharma a sizeable victory, allowing the companies to extend life times of brand name drugs by selling them at discounted prices within the Medicare drug plan.

The latest deal is once again being portrayed as a magnanimous gesture by the profitable pharmaceutical makers–and to help the poor guys out a little and lessen the strain on their stockholders’s pocketbooks, the government apparently will come in to pay the companies some of the dough they lose in providing discounts. To put it another way, it looks like the discounts aren’t really discounts at all. In the world of Congressional smoke and mirrors, they miraculously become a subsidy.

Government policy ought  to push less expensive generic drugs into the marketplace. Mandating their preferred use by Medicare would be one small step in that direction. Generally speaking, the brand name drugs should be eliminated when their patents run out. The proposed legislation apparently will have the effect of lengthening the drug companies’  monopoly on certain drugs, thereby assuring higher, not lower prices.

Although somewhat confusing, an article in yesterday’s New York Times has details on the latest deal. And I’ve written before on how discounts are transformed into profits for Big Pharma–see the following posts:

Big Pharma’s Phony “Gift” to Seniors

More on the Pharma Con Job

 Bottom line: cost control is sacrificed to market monopoly

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s